Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Potential New Modes of Treatment of Neurotrophic Keratopathy

Yanai, Ryoji MD, PhD; Nishida, Teruo MD, DSc; Chikama, Tai-Ichiro MD, PhD; Morishige, Naoyuki MD, PhD; Yamada, Naoyuki MD, PhD; Sonoda, Koh-Hei MD, PhD

doi: 10.1097/ICO.0000000000000587
Article
Buy

Abstract: The cornea focuses external light onto the retina, a function for which it must be transparent and possess a smooth surface. Homeostasis of the corneal epithelium is regulated by various humoral factors present in the tear fluid and by neural factors derived from the trigeminal nerve. Neurotrophic keratopathy (NK) is characterized by corneal epithelial disorders that result from impairment of trigeminal nerve function and a consequent deficiency of neural factors. The ideal mode of treatment for this condition is the regeneration of damaged trigeminal nerve fibers, but such therapy is not currently available. In this review, we describe established and potential new treatments of NK. Our research demonstrated that a combination of the neurotransmitter substance P and insulin-like growth factor 1 (IGF-1) has a synergistic stimulatory effect on corneal epithelial migration in vitro and on corneal wound closure in vivo. Furthermore, we identified the minimal amino acid sequences of substance P and IGF-1 required for this synergistic action based on the assumption that the clinical application of peptides corresponding to these sequences would have fewer side effects compared with the full-length molecules. Combination of the substance P-derived peptide FGLM-amide and the IGF-1-derived peptide SSSR promoted corneal epithelial wound healing in patients with NK.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01756456.

*Department of Ophthalmology, Graduate School of Medicine, Yamaguchi University, Ube City, Japan; and

Department of Ophthalmology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.

Reprints: Ryoji Yanai, MD, PhD, Department of Ophthalmology, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-Kogushi, Ube City, Yamaguchi 755-8505, Japan (e-mail: yanai@yamaguchi-u.ac.jp).

Supported by an award from the Japan Eye Bank Association (to R.Y.).

T. Nishida holds patents on FGLM-amide + SSSR eye drops. The other authors have no conflicts of interest to declare.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.